$557.93
0.93%
Nasdaq, Apr 21, 09:15 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$563.16
-115.26 16.99% 1M
-435.07 43.58% 6M
-149.17 20.94% YTD
-338.03 37.51% 1Y
-160.04 22.13% 3Y
-5.63 0.99% 5Y
+115.64 25.84% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+13.88 2.53%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $61.25b
Enterprise Value $55.18b
P/E (TTM) P/E ratio 14.71
EV/FCF (TTM) EV/FCF 15.06
EV/Sales (TTM) EV/Sales 3.89
P/S ratio (TTM) P/S ratio 4.31
P/B ratio (TTM) P/B ratio 2.10
Revenue growth (TTM) Revenue growth 8.27%
Revenue (TTM) Revenue $14.20b
EBIT (operating result TTM) EBIT $4.11b
Free Cash Flow (TTM) Free Cash Flow $3.66b
Cash position $9.01b
EPS (TTM) EPS $38.29
P/E forward 15.83
P/S forward 4.28
EV/Sales forward 3.86
Short interest 2.69%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Regeneron Pharmaceuticals forecast:

18x Buy
67%
8x Hold
30%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
67%
Hold
30%
Sell
4%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14,202 14,202
8% 8%
100%
- Direct Costs 2,453 2,453
10% 10%
17%
11,749 11,749
8% 8%
83%
- Selling and Administrative Expenses 2,516 2,516
16% 16%
18%
- Research and Development Expense 4,635 4,635
16% 16%
33%
4,597 4,597
2% 2%
32%
- Depreciation and Amortization 483 483
15% 15%
3%
EBIT (Operating Income) EBIT 4,114 4,114
4% 4%
29%
Net Profit 4,413 4,413
12% 12%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Positive
FXEmpire
about 7 hours ago
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Neutral
GlobeNewsWire
3 days ago
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all ap...
Positive
Reuters
3 days ago
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,106
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today